The Clinical Relevance of Rising CA-125 Levels Within the Normal Range in Patients With Uterine Papillary Serous Cancer

Frimer, Marina; Hou, June Y.; McAndrew, Thomas; Goldberg, Gary L.; Shahabi, Shohreh

doi:10.1177/1933719112459218

Cited by 15 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,20Y25 Also, the rise in CA-125 in the reference range was associated with recurrence. 26 In our present study, the preoperative serum CA-125 level was found to be a preoperative predictive risk factor for LN metastasis. This factor may therefore help to subgroup UPSC patients and identify cases who should definitely undergo comprehensive staging surgery.…”

Section: Discussionsupporting

confidence: 55%

Identification of a Preoperative Predictive Factor for Lymph Node Metastasis in Uterine Papillary Serous Carcinoma: Long-term Results From a Single Institution

Baek

Lee

Kim

et al. 2015

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 55%

Identification of a Preoperative Predictive Factor for Lymph Node Metastasis in Uterine Papillary Serous Carcinoma: Long-term Results From a Single Institution

Baek

Lee

Kim

et al. 2015

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“… 7 Consistent with the current literature, our data showed that elevated serum CA 125 level was associated with advanced stage and recurrent disease. 24 , 25 Therefore, women with elevated preoperative CA 125 levels may benefit from this comprehensive staging.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases

Wang¹,

Yu²,

Yang³

et al. 2018

CMAR

View full text Add to dashboard Cite

ObjectivesThe objectives of this study were to analyze clinicopathological features and to investigate the prognostic determinants in patients with uterine papillary serous carcinoma (UPSC).Materials and methodsA cohort of 106 UPSC patients diagnosed and treated at Peking Union Medical College Hospital between 2000 and 2016 were retrospectively reviewed. The Kaplan–Meier method and Cox regression analysis were used for survival analysis. Differences between categorical data were calculated by using the chi-squared test.ResultsThe median follow-up was 29.0 months (range =2–170 months), with an overall recurrence rate of 35.8%. The coincidence rate between preoperative endometrial sampling and postoperative definitive pathology of hysteroscopy group was significantly higher than that of the dilation and curettage group (88.5% vs 65.0%, P=0.019). Adjuvant therapy-treated patients with stage I UPSC experienced significantly fewer recurrences than those receiving observation (P=0.003). Patients with advanced-stage UPSC who received combination therapy demonstrated a lower risk of local recurrence compared with those who received chemotherapy alone with a borderline significance (P=0.051). Elevated serum cancer antigen 125 level was associated with advanced-stage disease and recurrence (P<0.001). In multivariate analysis, tumor stage and optimal cytoreduction were independent predictors of survival. In substage analysis, complete surgical staging was associated with better overall survival (OS; yes vs no, HR: 0.05 [95% CI: 0.01–0.51], P=0.037) in patients with stage I UPSC. As for advanced stage, paclitaxel–platinum chemotherapy regimen and optimal cytoreduction were independent favorable prognostic factors for progression-free survival (paclitaxel–carboplatin [TC] vs other; HR =0.38, P=0.010; yes vs no, HR =0.45, P=0.032) and OS (TC vs other, HR =0.38, P=0.022; yes vs no, HR =0.54, P=0.013).ConclusionIn patients with stage I UPSC, complete staging was associated with better OS, and therefore, it should be performed in all patients. Tumor stage and optimal cytoreduction are the most significant prognostic factors. Recurrence can be improved in stage I patients treated with adjuvant therapy and in patients with advanced-stage disease treated with combined therapy. TC regimen may be the preferred regimen for chemotherapy.

show abstract

“…CA‐125 can be used in the follow‐up of patients with high‐grade tumors and serous histology, as long as these tumors are altered at the time of diagnosis …”

Section: Resultsmentioning

confidence: 99%

“…[80][81][82] CA-125 can be used in the follow-up of patients with high-grade tumors and serous histology, as long as these tumors are altered at the time of diagnosis. 83 For patients with stage III and IV disease, chest, abdominal, and pelvic CT scans should be performed every 6 months for the first 3 years and every 6 to 12 months for the next 2 years. 84 Pelvic MRI can be performed in patients with persistent EC after 6 months with or without treatment failure.…”

mentioning

confidence: 99%

Brazilian Society of Surgical Oncology guidelines for surgical treatment of endometrial cancer in regions with limited resources

Ribeiro

Cintra

Barrozo

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background Approximately 70% of cancer‐related deaths occur in low‐ and middle‐income countries. In addition to social and racial inequalities, treatment options in these countries are usually limited because of the lack of trained staff and equipment, limited patient access to health services, and a small number of clinical guidelines. Objectives The Brazilian Society of Surgical Oncology developed this guideline to address these barriers and guide physicians treating patients with endometrial cancer (EC) in regions with limited resources and few specialized centers. Methods The guideline was prepared from 10 January to 25 October 20192019 by a multidisciplinary team of 56 experts to discuss the main obstacles faced by EC patients in Brazil. Thirteen questions considered critical to the surgical treatment of these patients were defined. The questions were assigned to groups that reviewed the literature and drafted preliminary recommendations. Following a review by the coordinators and a second review by all participants, the groups made final adjustments for presentations in meetings, classified the level of evidence, and voted on the recommendations. Results For all questions including staging, fertility spearing treatment, genetic testing, sentinel lymph node use, surgical treatment, and other clinical relevant questions, major agreement was achieved by the participants, always using accessible alternatives. Conclusions It is possible to provide adequate treatment for most EC patients in resource‐limited areas, but the first option should be referral to specialized centers with more resources.

show abstract

The Clinical Relevance of Rising CA-125 Levels Within the Normal Range in Patients With Uterine Papillary Serous Cancer

Cited by 15 publications

References 19 publications

Identification of a Preoperative Predictive Factor for Lymph Node Metastasis in Uterine Papillary Serous Carcinoma: Long-term Results From a Single Institution

Identification of a Preoperative Predictive Factor for Lymph Node Metastasis in Uterine Papillary Serous Carcinoma: Long-term Results From a Single Institution

Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases

Brazilian Society of Surgical Oncology guidelines for surgical treatment of endometrial cancer in regions with limited resources

Contact Info

Product

Resources

About